Your Partner in Every Patient’s Care
To refer a patient, call 212-731-6000 or browse our specialists.
Cancer
Practice-Changing Medicine
Innovative Strategy Drives Success in Refractory AML
A patient with KMT2A-rearranged AML achieved deep remission through menin inhibition before and after a high-risk third allogeneic transplant.
NYU Langone Health: A Leader in Cancer
Ranked Among the Nation’s Best Cancer Centers
An NCI Comprehensive Cancer Center
200+
active interventional therapeutic clinical trials
Complex Case Spotlight
Targeted Salvage Cryoablation Resolves Radio-Recurrent Prostate Cancer
Advanced Imaging Localizes Lesion & Rules Out Metastatic Disease
About 11 years after a diagnosis of prostate cancer treated with radiation therapy, a patient presented with progressively rising PSA levels. Multiparametric MRI revealed a lesion in the left medial posterior base peripheral zone; a subsequent MRI-ultrasound fusion biopsy demonstrated prostate cancer in 1 of 12 systematic cores and 3 of 3 targeted cores obtained from the lesion. An 18F-fluciclovine whole-body PET CT supported the conclusion of a local recurrence and found no evidence of metastatic disease.
Prostate imaging. A) Axial T2 MRI scan showing PI-RADS 5 lesion. B) Apparent diffusion coefficient map with corresponding region of restricted diffusion. C) 18F-fluciclovine PET demonstrating uptake in the left posterior prostate.
1 of 3
Salvage Cryoablation Treats Prostate Cancer Recurrence
Salvage partial gland cryoablation deploys the energy in a smaller and more focal treatment volume and at a slower rate to minimize the higher risk for side effects in a post-radiation setting. For the procedure, six V-probes were placed into the left posterior hemi-prostate, with six thermocouple probes at treatment boundaries to provide intraoperative temperature assessment of the margins.
Post-ablation imaging. A) Pretreatment MRI. B) Four-year post-ablation MRI showing no evidence of tumor.
2 of 3
Post-Treatment PSA Monitoring Affirms Successful Cancer Therapy
To be successful, salvage focal cryoablation requires careful patient selection and a meticulous treatment application; in addition, monitoring patients with serial PSA and MRI can provide essential clinical endpoints. Four years after the salvage cryoablation procedure, regular PSA monitoring has found no evidence of prostate cancer in the patient.
The patient’s PSA levels.
3 of 3
The Best Experts and Latest Breakthroughs
Select your specialty to receive updates on our pioneering research, innovations, expert perspectives, case studies, practice-changing medicine, and more.